Naslund Medical AB

What Naslund Medical AB does

Naslund Medical AB is a Swedish medical device company founded in 2005 and headquartered in Huddinge, Sweden, that develops and markets Gold Anchor, a patented fiducial marker system for image-guided radiotherapy (IGRT) and surgical oncology. The core product is a soft-tissue marker made from a proprietary gold-iron alloy (0.5% iron in the standard variant, 1.5% iron in the MR+ variant), pre-loaded inside ultra-thin needles ranging from 25-gauge (0.5mm) to 20-gauge (0.9mm). The patented folding marker design allows the marker to fold inside tissue, providing immediate stabilization and minimizing migration, enabling a shorter lead time between implantation and treatment planning. The Gold Anchor MR+ variant is engineered for superior MRI visibility to support MR-only radiotherapy planning workflows. The technology was invented by Dr. Ingemar Näslund, co-inventor of the SBRT technique in 1991 and former head of the Division of Radiation Therapy at Radiumhemmet, Karolinska University Hospital for 20 years; the product is supported by 45+ peer-reviewed clinical publications covering prostate, lung, liver, pancreas, breast, cervical, esophageal, and rectal indications.

Name

Naslund Medical AB

Legal name

Naslund Medical AB

Website

https://goldanchormarker.com

Company type

Private

Founded year

2005

Operating status

Acquired

Headcount range

1–10 employees

Short description

Naslund Medical AB is a Swedish medical device company developing and marketing the Gold Anchor fiducial marker system — patented gold-iron alloy markers pre-loaded in ultra-thin needles — for image-guided radiotherapy and surgical oncology, sold globally to cancer treatment centers.

Ownership category

akta.pro rank

Product category

Radiation Oncology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

Keywords

• Fiducial markers
• Image-guided radiotherapy
• Radiation oncology devices
• Soft tissue markers
• Proton therapy markers

Headquarters

HQ city

Huddinge

HQ country

Sweden

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Medical Device Sales - Fiducial Marker Products: Naslund Medical generates revenue primarily through the sale of Gold Anchor fiducial marker products. The company sells pre-loaded needle/marker kits and introducer devices to radiotherapy departments and cancer treatment centers worldwide. Products are sold in boxes of 10 units per product code. Revenue was approximately £7 million for the year to March 2026 (unaudited).

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Naslund Medical AB develops, manufactures, and markets Gold Anchor, a proprietary soft-tissue fiducial marker system made from a patented gold-iron alloy pre-loaded inside ultra-thin needles (25G to 20G). The markers enable precise tumor localization for image-guided radiotherapy (IGRT), stereotactic body radiotherapy (SBRT), proton and carbon-ion therapy, and surgical guidance. Products are sold in boxes of 10 units to radiotherapy departments and cancer treatment centers worldwide.

Product overview

Naslund Medical AB offers a portfolio of implantable soft-tissue fiducial markers for cancer radiotherapy and surgical guidance. The core product line includes the Gold Anchor Marker (gold-iron alloy in 20G-25G needles) and Gold Anchor MR+ (enhanced MRI visibility variant with 1.5% iron). The Gold Anchor Introducer enables endoscopic marker placement. Products are sold in boxes of 10 units with various needle lengths (8-35cm) and marker sizes to accommodate different treatment sites including prostate, lung, liver, pancreas, breast, and abdominal organs. The company operates from Sweden with subsidiaries in the US, UK, and France.

Differentiator

Problem solved

Functional benefit

Brands

• Gold Anchor: Fiducial marker product line used for targeted cancer treatment in radiotherapy and surgical procedures
• Gold Anchor MR+
• Gold Anchor Introducer

Products and services

• Gold Anchor Marker A soft-tissue fiducial marker made of gold-iron alloy pre-loaded inside thin needles, used to radiographically mark soft tissue for image-guided radiotherapy (IGRT) and surgical guidance. Available in multiple sizes (0.28mm and 0.40mm diameter; 10mm and 20mm length) and delivered pre-loaded in sterilized needles ranging from 20G to 25G. Sold in boxes of 10 units for radiotherapy departments and cancer treatment centers.
• Gold Anchor MR+ Enhanced version of the Gold Anchor marker containing 98.5% pure gold and 1.5% pure iron alloy, specifically designed for superior MRI visibility while maintaining compatibility with CT, kV imaging, and radiotherapy treatment systems. Optimized for MR-only planning workflows and MR-guided radiotherapy systems.
• Gold Anchor Introducer A specialized device used to transfer Gold Anchor markers into 22G endoscopic ultrasound (EUS) aspiration needles for placement in rectal, esophageal, pancreatic, and central lung tumors during endoscopic procedures. Delivered pre-loaded with Gold Anchor MR+ marker inside, sterilized and ready for use.

Quantifiable outcome

• 98% CTV dose coverage achieved using fiducial markers, comparable to MR-Linac; CBCT without fiducial markers achieves only 62% CTV dose coverage
• +6 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

Feature6 records

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Brainlab: Brainlab provides ExacTrac Dynamic image-guided radiotherapy positioning software used with Gold Anchor markers. Brainlab's surgical and radiotherapy software platforms create both a partnership channel and a competitive risk if Brainlab bundles proprietary markers with its tracking systems.
• Halma PLC Healthcare Segment: Halma's broader healthcare segment includes IZI Medical, Volk Optical, and other niche medical device businesses. Post-acquisition, Naslund Medical will be benchmarked and integrated with these peer Halma healthcare assets, sharing back-office, regulatory, and commercial resources.
• Elekta: Elekta manufactures linear accelerators (Versa HD, Unity) and radiation oncology treatment planning systems including XVI CBCT. As a primary integration partner for Gold Anchor markers, Elekta's competitive moves and product roadmap directly shape Naslund Medical's addressable market.
• IZI Medical Products: IZI Medical is Naslund Medical's new sister company under Halma PLC's healthcare segment following the July 2026 acquisition. Specializes in spinal implants, vertebroplasty, and image-guided intervention products, with overlapping physician relationships in interventional radiology and oncology.
• Accuray: Accuray manufactures CyberKnife and Radixact systems for robotic and helical radiotherapy, both of which integrate with Gold Anchor markers via Synchrony real-time motion tracking. Accuray is a complementary rather than competing equipment partner, but holds leverage over compatibility decisions.
• IBA (Ion Beam Applications): IBA is a global leader in proton therapy equipment, with ProteusONE and ProteusPLUS installations worldwide. As proton therapy centers expand (Gold Anchor is used at Osaka HIMAK, NCCS, University of Florida), IBA represents the equipment ecosystem within which Naslund Medical's particle-therapy markers compete.
• Varian Medical Systems (Siemens Healthineers): Varian is the global market leader in linear accelerators and radiation oncology software. While not a direct fiducial marker manufacturer, Varian's TrueBeam and Ethos systems dictate workflow integration that Naslund Medical's Gold Anchor must support, making it a critical ecosystem player.

Direct peers

• CIVCO Radiotherapy: CIVCO is a leading manufacturer of fiducial markers, immobilization devices, and accessories for image-guided radiotherapy. Directly competes with Naslund Medical in the soft-tissue fiducial marker category across prostate, lung, and other anatomic sites, including the widely used Gold Markers line.
• Best Medical International: Best Medical manufactures brachytherapy seeds, fiducial markers, and radiotherapy accessories. Competes with Naslund Medical in the prostate and soft-tissue fiducial segment and is similarly focused on the radiation oncology customer base.

Emerging players

• ViewRay: ViewRay pioneered MR-guided radiotherapy (MRIdian system) — an emerging workflow for which Gold Anchor MR+ is specifically designed. As MR-Linac and MR-guided systems proliferate, ViewRay and competitors like Elekta Unity represent the addressable market for MR-optimized fiducials.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Naslund Medical AB